Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma

This study is testing a combination of two cancer drugs — apatinib (a targeted therapy) and camrelizumab (an immunotherapy) — together with a minimally invasive procedure called TACE (chemotherapy delivered directly to the liver) as treatment before surgery in patients with liver cancer (hepatocellular carcinoma). The goal is to shrink the tumor enough to allow successful removal. **You may be eligible if...** - You are between 18 and 70 years old - You have liver cancer confirmed by biopsy or pathology - You have not received any prior cancer treatment - Your cancer is centrally located in the liver (BCLC stage B) but surgery is possible after specialist review - Your liver function is adequate (Child-Pugh A or B with 7 or fewer points) - You have at least one measurable tumor **You may NOT be eligible if...** - Your cancer is a mixed type (not pure hepatocellular carcinoma) - You have another previous cancer history - Your cancer has spread outside the liver or into major blood vessels - You have had an organ transplant or immune deficiency - You have significant fluid buildup around organs or serious cardiovascular/respiratory conditions - You have had a blood clot or stroke in the past 6 months - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.